A subject of the present invention is to find utility of a co mbination of a Rho kinase inhibitor having a novel action and a beta -blocker as a therapeutic agent for glaucoma. Actions of reduci ng intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the beta -blocker. For the administration mode, each drug can be administered in combination or in mixture.